Century Therapeutics (IPSC) Net Income towards Common Stockholders Growth (3y) (2023 - 2026)

Century Therapeutics (IPSC) Net Income towards Common Stockholders Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.30%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 10.23%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 71.02%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 37.89%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 25.99%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -38.56%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 37.44%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 62.15%
10 Century Therapeutics 346.65 Mn 86.58 Mn - -39.49%

Historic Data

Download Data
DateValue
Jun 30, 2026 -39.49%
Mar 31, 2026 -42.73%
Dec 31, 2025 32.96%
Sep 30, 2025 -3.83%
Jun 30, 2025 -1.64%
Mar 31, 2025 59.28%
Dec 31, 2024 -8.21%
Sep 30, 2024 -6.28%
Jun 30, 2024 -10.27%
Mar 31, 2024 -15.22%
Dec 31, 2023 -36.20%
Sep 30, 2023 -35.29%
Jun 30, 2023 -28.78%